Novartis has agreed to buy The Medicines Company for $85 per share in a $9.7 billion cash transaction, a price that it might have overpaid. Though it’s buying the entire firm, the deal is really just about one drug: cardiovascular contender inclisiran.
The Medicines Company's inclisiran, boasting a similar efficacy and safety profile but better convenience, could become the PCSK9 of choice, one analyst says.
